Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2024-08-01 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押展期及解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge extension and release of shares held by a controlling shareholder of the company. It details the number of shares pledged, the pledge periods, and the release of pledged shares. There is no financial statement, earnings data, or management discussion. The content is about share pledging activities by a major shareholder, which fits the category of announcements related to shareholding and capital structure changes. This is not a full financial report, earnings release, or management report. It is specifically about share pledge and release, which aligns with the category 'Capital/Financing Update (CAP)'. The document length is short and it is not an announcement of a report publication but a direct disclosure of share pledge details. Therefore, the correct classification is CAP with high confidence.
2024-08-01 Chinese
关于获得创新药HSK39004吸入混悬液《药物临床试验批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving approval from the National Medical Products Administration for clinical trials of a new innovative drug. It includes details about the drug, regulatory approval, and risk warnings. The document is short (873 characters) and serves as an official notification rather than a detailed report or financial statement. It does not contain financial data, management changes, or meeting materials. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2024-07-25 Chinese
关于控股股东部分股份质押展期的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the extension of a pledge on shares held by a controlling shareholder. It details the number of shares pledged, the pledge period extension, and related shareholder information. There is no financial report, earnings data, or management discussion. The content is about a shareholder's share pledge extension, which is a capital-related update but not a new share issue or capital change. This fits best under Capital/Financing Update (CAP) as it concerns financing activities related to share pledges by a controlling shareholder.
2024-07-19 Chinese
关于获得创新药HSK21542注射液新适应症IND申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving an acceptance notice from the National Medical Products Administration for a new indication clinical trial application of an innovative drug. It details the drug, the indication, regulatory acceptance, and risk warnings. The document is short (1226 characters) and does not contain financial statements or detailed financial data. It is an announcement of a regulatory acceptance related to drug development, not a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-07-14 Chinese
2024年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2024, issued by the company. It provides estimated financial results including net profit and earnings per share, and explains reasons for changes in performance. It explicitly states that the financial data have not been audited and that detailed financial data will be disclosed in the 2024 half-year report. The document is short (1264 characters) and serves as a preliminary earnings forecast rather than a full interim report containing actual financial statements or substantive financial data. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. H1 2024
2024-07-11 Chinese
关于获得1类创新药苯磺酸克利加巴林胶囊新适应症《药品注册证书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from 海思科医药集团股份有限公司 regarding the receipt of a new drug registration certificate for an innovative drug with a new indication. It details the drug name, registration number, approval details, and a brief description of the drug and its clinical use. The document is short (1223 characters) and serves as a formal public announcement of regulatory approval rather than a detailed financial or operational report. There is no financial data, no mention of annual or quarterly results, no management discussion, no voting results, or other report types. It is clearly an official announcement about a regulatory milestone related to product approval. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-07 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.